*shared during the HAI/Wemos event on Transparency in Brussels by MdM France @piotrjankol.bsky.social @rozscourse.bsky.social @mattherder.bsky.social @javierpadillab.bsky.social

If approved, it would set a major European precedent. Even if it doesn’t pass this time, this amendment brings a bit of hope at a moment when confidentiality clauses and trade secrets are tightening their grip on drug prices and R&D data across regions /6

This amendment (n° AS118) is not yet law — it was tabled by the Socialist group during the debate on the 2026 Social Security Financing Bill and adopted in committee.

It still needs to survive the rest of the legislative process. /5

And there’s a strong enforcement proposal:

Companies with annual revenue over €20 billion that fail to declare public R&D funding could be fined 0.5 % of their global turnover, with the money going to France’s national health insurance fund. /4

They’d also need to publish:

.annual R&D and marketing spend

.prices, reimbursement terms, and sales in other European countries

All of this would appear in the annual report of France’s Economic Committee for Health Products. /3

The amendment would require pharma companies to disclose:

.IP status and any mergers or acquisitions

.the public and private research behind each drug

.sources of funding — including public R&D investment — for the development of each medicine.

All of this would become public. /2

@pgullon.bsky.social @javierpadillab.bsky.social @sergioefe.bsky.social

The article calls for a shift: to recognize racism as a fundamental determinant of health and to build policies and practices that reflect that reality.

Health equity demands confronting power — and naming racism for what it is.

We argue that public health system still functions under a paradigm of denial — one that dismisses race as a valid analytical category and attributes inequities to class or migration status instead.

This erases how structural racism shapes who gets sick, who gets treated, and who gets left behind.